Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
|Podcasts|September 14, 2021
Challenges and Unmet Needs in the Treatment of HER2-Positive Breast Cancer
Author(s)OncLive Staff
In the first segment, Dr Pegram and colleagues highlight some of the challenges and remaining unmet needs in the management of patients with HER2-positive breast cancer.
Advertisement
Advertisement
Related to this article
Check out this October recap of OncLive’s coverage of the top news and expert insights in breast cancer.
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.
Erica L. Mayer, MD, MPH, discusses the FDA approval of camizestrant for ESR1-mutated HR+/HER2– breast cancer and the importance of ctDNA monitoring.
Advertisement
Advertisement
Trending on OncLive
1
Cardiovascular and Bleeding Risk With BTK Inhibitors in CLL
2
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
3
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
4
Expanding Clinical Trial Access Through Community Oncology
5